Hubbry Logo
search button
Sign in
Avitriptan
Avitriptan
Comunity Hub
arrow-down
History
arrow-down
starMore
arrow-down
bob

Bob

Have a question related to this hub?

bob

Alice

Got something to say related to this hub?
Share it here.

#general is a chat channel to discuss anything related to the hub.
Hubbry Logo
search button
Sign in
Avitriptan
Community hub for the Wikipedia article
logoWikipedian hub
Welcome to the community hub built on top of the Avitriptan Wikipedia article. Here, you can discuss, collect, and organize anything related to Avitriptan. The purpose of the hub is to connect people, fos...
Add your contribution
Avitriptan
Avitriptan
Clinical data
Other namesBMS-180048; BMS-180,048; BMS180048
Drug classSerotonin 5-HT1B and 5-HT1D receptor agonist; Antimigraine agent; Triptan
ATC code
  • None
Legal status
Legal status
  • Never marketed
Identifiers
  • 1-[3-[3-[4-(5-methoxypyrimidin-4-yl)piperazin-1-yl]propyl]-1H-indol-5-yl]-N-methyl-methanesulfonamide
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H30N6O3S
Molar mass458.58 g·mol−1
3D model (JSmol)
  • O=S(=O)(NC)Cc1ccc2c(c1)c(c[nH]2)CCCN4CCN(c3ncncc3OC)CC4
  • InChI=1S/C22H30N6O3S/c1-23-32(29,30)15-17-5-6-20-19(12-17)18(13-25-20)4-3-7-27-8-10-28(11-9-27)22-21(31-2)14-24-16-26-22/h5-6,12-14,16,23,25H,3-4,7-11,15H2,1-2H3 checkY
  • Key:WRZVGHXUPBWIOO-UHFFFAOYSA-N checkY
  (verify)

Avitriptan (INNTooltip International Nonproprietary Name; development code BMS-180048) is an antimigraine drug of the triptan family which was never marketed.[1] It acts as a serotonin 5-HT1B and 5-HT1D receptor agonist.[1][2] The drug reached phase 3 clinical trials prior to the discontinuation of its development.[3]

Pharmacology

[edit]
Avitriptan activities
Target Affinity (Ki, nM)
5-HT1A 19 (Ki)
646–>10,000 (EC50Tooltip half-maximal effective concentration)
5-HT1B 1.6–21 (Ki)
2.1–2.7 (EC50)
5-HT1D 0.78–4.4 (Ki)
0.54 (EC50)
5-HT1E 3,550 (Ki)
3,020–>10,000 (EC50)
5-HT1F 78–182 (Ki)
81–891 (EC50)
5-HT2A 2,340 (Ki)
123 (EC50)
5-HT2B 1,150 (Ki)
389 (EC50)
5-HT2C ND (Ki)
ND (EC50)
5-HT3 >1,000 (rat)
5-HT4 ND
5-HT5A ND
5-HT6 ND
5-HT7 759 (Ki)
4,170 (EC50)
α1Aα1D ND
α2Aα2C ND
β1β3 ND
D1D5 ND
H1H4 ND
M1M5 ND
I1, I2 ND
σ1, σ2 ND
TAAR1Tooltip Trace amine-associated receptor 1 ND
SERTTooltip Serotonin transporter ND
NETTooltip Norepinephrine transporter ND
DATTooltip Dopamine transporter ND
Notes: The smaller the value, the more avidly the drug binds to the site. All proteins are human unless otherwise specified. Refs: [1][4][2]

Avitriptan acts as a selective serotonin 5-HT1B and 5-HT1D receptor agonist.[1][2] It is also notable in being a weak serotonin 5-HT2A receptor agonist (EC50Tooltip half-maximal effective concentration = 123 nM), albeit with about two orders of magnitude lower activational potency than at the serotonin 5-HT1B and 5-HT1D receptors.[2]

Besides its activities at serotonin receptors, avitriptan has been found to act as a weak aryl hydrocarbon receptor agonist.[5]

Chemistry

[edit]

Avitriptan is a triptan and a modified analogue of tryptamines like the psychedelic drug dimethyltryptamine (DMT).[6] However, avitriptan itself is not technically a tryptamine as it features a propylamine side chain instead of the ethylamine side chain present in tryptamines.[6] Besides this difference, avitriptan is substituted at the 5 position of the indole ring system and the amine moiety has been cyclized and extended.[6]

The predicted log P of avitriptan is 1.8.[6]

See also

[edit]

References

[edit]
  1. ^ a b c d Saxena PR, De Vries P, Wang W, et al. (February 1997). "Effects of avitriptan, a new 5-HT 1B/1D receptor agonist, in experimental models predictive of antimigraine activity and coronary side-effect potential". Naunyn-Schmiedeberg's Archives of Pharmacology. 355 (2): 295–302. doi:10.1007/pl00004946. hdl:1765/66501. PMID 9050026. S2CID 25137165. Archived from the original on 1999-10-23.
  2. ^ a b c d Rubio-Beltrán E, Labastida-Ramírez A, Haanes KA, van den Bogaerdt A, Bogers AJ, Zanelli E, Meeus L, Danser AH, Gralinski MR, Senese PB, Johnson KW, Kovalchin J, Villalón CM, MaassenVanDenBrink A (December 2019). "Characterization of binding, functional activity, and contractile responses of the selective 5-HT1F receptor agonist lasmiditan". British Journal of Pharmacology. 176 (24): 4681–4695. doi:10.1111/bph.14832. PMC 6965684. PMID 31418454. TABLE 1 Summary of pIC50 (negative logarithm of the molar concentration of these compounds at which 50% of the radioligand is displaced) and pKi (negative logarithm of the molar concentration of the Ki ) values of individual antimigraine drugs at 5‐HT receptors [...] TABLE 2 Summary of pEC50 values of cAMP (5‐HT1A/B/E/F and 5‐HT7), GTPγS (5‐HT1A/B/D/E/F), and IP (5‐HT2) assays of individual antimigraine drugs at 5‐HT receptors [...]
  3. ^ "Delving into the Latest Updates on Avitriptan with Synapse". Synapse. 19 July 2025. Retrieved 29 July 2025.
  4. ^ Ramadan NM, Skljarevski V, Phebus LA, Johnson KW (October 2003). "5-HT1F receptor agonists in acute migraine treatment: a hypothesis". Cephalalgia. 23 (8): 776–785. doi:10.1046/j.1468-2982.2003.00525.x. PMID 14510923.
  5. ^ Vyhlídalová B, Krasulová K, Pečinková P, Poulíková K, Vrzal R, Andrysík Z, Chandran A, Mani S, Dvorak Z (April 2020). "Antimigraine Drug Avitriptan Is a Ligand and Agonist of Human Aryl Hydrocarbon Receptor That Induces CYP1A1 in Hepatic and Intestinal Cells". Int J Mol Sci. 21 (8): 2799. doi:10.3390/ijms21082799. PMC 7216230. PMID 32316498.
  6. ^ a b c d "Avitriptan". PubChem. Retrieved 29 July 2025.